GENE THERAPY FOR BRAIN TUMORS

脑肿瘤的基因治疗

• 批准号: 7349527
• 负责人: R. PAUL JOHNSON
• 金额: $ 4.89万
• 依托单位: HARVARD MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-05-01 至 2007-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7349527
• 关键词: GENE; THERAPY; BRAIN; TUMORS

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Malignant gliomas constitute one of the brain tumors that are most refractory to treatment. Herpes simplex virus (HSV) vectors are being tested for selective delivery of drug-enhancing genes to tumor cells. The goal of this project is to investigate the contribution of immune mechanisms to HSV-mediated oncolysis. Immune responses to HSV vectors and their effect on tumor regression are being evaluated in common marmoset monkeys. It is hypothesized that cytolytic T lymphocytes to HSV vectors selectively targeting tumor cells will enhance virus-induced oncolysis.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。恶性神经胶质瘤是最难治疗的脑肿瘤之一。单纯疱疹病毒（HSV）载体正在测试选择性递送药物增强基因到肿瘤细胞。本项目的目标是研究免疫机制对HSV介导的溶瘤作用的贡献。对HSV载体的免疫应答及其对肿瘤消退的影响正在普通绒猴中进行评估。假设选择性靶向肿瘤细胞的HSV载体的细胞溶解性T淋巴细胞将增强病毒诱导的溶瘤作用。